Interleukin-1 alpha and beta, TNF-alpha and HTTLPR gene variants study on alcohol toxicity and detoxification outcome.
Genetic factors may influence the liability to treatment outcome and medical complications in alcoholism. In the present study we investigated the IL-1A rs1800587, IL-1B rs3087258, TNF-alpha rs1799724 and the HTTLPR variants in a sample of 64 alcohol dependents and 47 relatives versus a set of clinical parameters and outcome measures. Alcohol dependents had a less favorable clinical profile compared to relatives (higher cholesterol, triglycerides, glucose, glutamic oxaloacetic transaminase, glutamic pyruvic transaminase, gamma-glutamyltransferase). After detoxification, all clinical indexes improved and hepatic enzyme levels were similar in alcohol dependents and relatives, except for the GGT that remained significantly higher in alcohol dependents. Alcoholic depressive and anxiety scores were significantly reduced after detoxification. IL-1A, IL-1B, TNF-alpha and HTTLPR variants were not associated with any baseline clinical index or change after detoxification. In our sample IL-1A, IL-1B, TNF-alpha and HTTLPR do not appear as liability factors for alcohol toxicity or detoxification outcome, however the small sample size may influence the observed results.
Serretti
Alessandro
A
Institute of Psychiatry, University of Bologna, Bologna, Italy. alessandro.serretti@unibo.it
Liappas
Ioannis
I
Mandelli
Laura
L
Albani
Diego
D
Forloni
Gianluigi
G
Malitas
Petros
P
Piperi
Christina
C
Zisaki
Aikaterini
A
Tzavellas
Elias O
EO
Papadopoulou-Daifoti
Zeta
Z
Prato
Francesca
F
Batelli
Sara
S
Pesaresi
Marzia
M
Kalofoutis
Anastasios
A
D000328:Adult; D020268:Alcohol-Induced Disorders, Nervous System / Q000235:genetics* / Q000276:immunology / Q000503:physiopathology; D000437:Alcoholism / Q000235:genetics* / Q000276:immunology / Q000503:physiopathology; D002784:Cholesterol / Q000378:metabolism; D016207:Cytokines / Q000235:genetics* / Q000276:immunology; D004351:Drug Resistance / Q000235:genetics / Q000276:immunology; D004734:Energy Metabolism / Q000502:physiology; D005260:Female; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D014644:Genetic Variation / Q000235:genetics; D005947:Glucose / Q000378:metabolism; D006801:Humans; D008658:Inactivation, Metabolic / Q000502:physiology; D007375:Interleukin-1 / Q000235:genetics / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011401:Promoter Regions, Genetic / Q000235:genetics; D050486:Serotonin Plasma Membrane Transport Proteins / Q000235:genetics*; D013375:Substance Withdrawal Syndrome / Q000235:genetics* / Q000276:immunology / Q000503:physiopathology; D014280:Triglycerides / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000276:immunology
D016207:Cytokines; D007375:Interleukin-1; D050486:Serotonin Plasma Membrane Transport Proteins; D014280:Triglycerides; D014409:Tumor Necrosis Factor-alpha; D002784:Cholesterol; D005947:Glucose